Rexahn Pharmaceuticals Inc Recap

What is your opinion of Rexahn Pharmaceuticals Inc?

Rexahn Pharmaceuticals Inc

AMEX:RNN - May. 22nd 11:28am

RNN
Rexahn Pharmaceuticals Inc’s alternate profiles:
$ 0.745 0.025 (3.47%)

Shares of Rexahn Pharmaceuticals Inc – a $133.5 million market cap Biotechnology & Medical Research company – have risen 3.47 percent to $0.745 as of 7:59 PM. With the current share price, Rexahn Pharmaceuticals Inc has a P/E Ratio of 0.00.

Rexahn Pharmaceuticals, Inc. is a development stage biopharmaceutical company dedicated to the discovery, development and commercialization of treatments for cancer and other medical needs. The Company’s focus is on three clinical stage drug candidates in active development, which are Archexin (Phase IIa completed); RX-3117 (Phase Ib initiated) and Supinoxin (RX-5902, Phase I trial initiated). In addition to these drug candidates, the Company has two clinical stage drug candidates for indications other than cancer: Serdaxin, for major depressive disorder; and Zoraxel, for sexual dysfunction. The Company also has three drug candidates in pre-clinical development: Archexin-Nano,for clinical benefits; RX-0047-Nano, for cancer cell survival, and RX-21101, for treatment of tumors. The Company is also working on research technologies, including multi-target aimed ligands platform and nano-based drug delivery systems.

Find out more about Rexahn Pharmaceuticals Inc.


Rexahn Pharmaceuticals Inc Stock Price

Rexahn Pharmaceuticals Inc’s (AMEX:RNN) current stock price is $0.745, up $0.025.

ROCKVILLE, MD | 15 hours ago

Financials
Rexahn Pharmaceuticals Inc